XTL Biopharma Schedules Shareholder Meeting for April 30
Ticker: XTLB · Form: 6-K · Filed: Mar 21, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
XTL Bio calling shareholder meeting April 30th - big decisions ahead.
AI Summary
XTL Biopharmaceuticals Ltd. announced on March 20, 2024, that it will hold an Extraordinary General Meeting of Shareholders on April 30, 2024, at 4:00 p.m. Israel time. The meeting will take place at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, in Bnei Brak, Israel.
Why It Matters
This meeting is a crucial step for XTL Biopharmaceuticals to potentially make significant decisions regarding its future operations or strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a shareholder meeting, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Registrant
- March 20, 2024 (date) — Announcement date
- April 30, 2024 (date) — Shareholder meeting date
- Doron Tikotzky Kantor Gutman & Amit Gross (company) — Company's attorneys
FAQ
What is the purpose of the Extraordinary General Meeting of Shareholders?
The filing does not explicitly state the purpose of the meeting, only that it will be held and that a Notice and Proxy Statement will be furnished.
Where will the Extraordinary General Meeting of Shareholders be held?
The meeting will be held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, located at 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel.
What time is the shareholder meeting scheduled for?
The meeting is scheduled for 4:00 p.m. Israel time.
What is the exact date of the announcement regarding the shareholder meeting?
The announcement was made on March 20, 2024.
Does XTL Biopharmaceuticals file annual reports under Form 20-F or 40-F?
XTL Biopharmaceuticals indicates it files annual reports under Form 20-F.
Filing Stats: 375 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-03-21 16:31:56
Filing Documents
- ea0202214-6k_xtlbio.htm (6-K) — 17KB
- ea020221401ex99-1_xtlbio.htm (EX-99.1) — 117KB
- ea020221401ex99-2_xtlbio.htm (EX-99.2) — 41KB
- ea020221401ex99-3_xtlbio.htm (EX-99.3) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- ex99-2_001.jpg (GRAPHIC) — 3KB
- ex99-3_001.jpg (GRAPHIC) — 529KB
- ex99-3_002.jpg (GRAPHIC) — 321KB
- 0001213900-24-024787.txt ( ) — 1356KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XTL BIOPHARMACEUTICALS LTD. Date: March 21, 2024 /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 3